Followers | 130 |
Posts | 18112 |
Boards Moderated | 0 |
Alias Born | 01/16/2007 |
Sunday, June 23, 2013 2:51:56 AM
-----------------------------------------------------------------------------------------------------------------------------------------------------
Hannover House (HHSE) Key Financial Ratios - Q1 2013
Market CAPitalization (June 21) = $6,273,813
Pre-Tax Profit Margin = 80.7%
Earnings Per Share = $0.0027
Price-Earnings - P/E Ratio = 4.22
Current Ratio = 3.49
Net Working Capital = $6,274,451
Debt-Equity Ratio = .13
Book Value Per Share = $.046
Price-to-Book Value = 0.248
Actual HHSE Metrics Calculations
HHSE Market CAPitalization (Total Dollar Market Value):
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89284101
HHSE Pre-Tax Profit Margin (Profitability Percentage):
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89284629
HHSE Earnings Per Share (Profitability):
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89283822
HHSE Price-Earnings - P/E Ratio (Valuation):
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89283915
HHSE Current Ratio (Liquidity):
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89282843
HHSE Net Working Capital (Operating Liquidity):
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89282892
HHSE Debt-Equity Ratio (Debt Measurement):
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89282964
HHSE Book Value Per Share (Liquidation Value):
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89283012
HHSE Price-to-Book Value (Stock Price Evaluation):
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89283365
Key Financial Ratios:
http://www.thecorys.com/babs/key_financial_ratios.htm
1st Quarter 2013 - Quarterly Report - Financial Results and Disclosures for P/E 3-31-2013:
https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=106892
All HHSE Financials & Filings:
http://www.otcmarkets.com/stock/HHSE/filings
HHSE
Recent HHSE News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 07:17:02 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM